Structure Therapeutics (NASDAQ:GPCR) Sets New 52-Week Low – Should You Sell?

Structure Therapeutics Inc. (NASDAQ:GPCR) shares hit a new 52-week low on Tuesday . The company traded as low as $26.03 and last traded at $26.63, with a volume of 791474 shares. The stock had previously closed at $29.04.

Analysts Set New Price Targets

Several research firms have recently issued reports on GPCR. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a report on Thursday, December 19th. JMP Securities reissued a “market outperform” rating and issued a $91.00 target price on shares of Structure Therapeutics in a report on Wednesday, December 18th. Morgan Stanley started coverage on Structure Therapeutics in a report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a research report on Monday, September 23rd. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $86.50.

Structure Therapeutics Stock Performance

The stock has a fifty day simple moving average of $33.66 and a 200 day simple moving average of $37.39. The firm has a market cap of $1.55 billion, a P/E ratio of -36.65 and a beta of -3.41.

Institutional Investors Weigh In On Structure Therapeutics

Large investors have recently bought and sold shares of the business. Principal Financial Group Inc. purchased a new stake in shares of Structure Therapeutics during the 2nd quarter valued at about $6,489,000. Natixis Advisors LLC boosted its holdings in Structure Therapeutics by 29.4% in the second quarter. Natixis Advisors LLC now owns 19,005 shares of the company’s stock worth $746,000 after purchasing an additional 4,321 shares during the last quarter. TD Asset Management Inc grew its position in Structure Therapeutics by 47.9% in the 2nd quarter. TD Asset Management Inc now owns 211,590 shares of the company’s stock worth $8,309,000 after purchasing an additional 68,490 shares during the period. Pier Capital LLC raised its stake in Structure Therapeutics by 3.7% during the 2nd quarter. Pier Capital LLC now owns 101,204 shares of the company’s stock valued at $3,974,000 after buying an additional 3,647 shares during the last quarter. Finally, American Century Companies Inc. lifted its holdings in shares of Structure Therapeutics by 66.4% during the 2nd quarter. American Century Companies Inc. now owns 434,982 shares of the company’s stock valued at $17,082,000 after buying an additional 173,523 shares during the period. 91.78% of the stock is currently owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.